Amgen, Inc. (NASDAQ:AMGN) was the target of some unusual options trading on Friday. Investors acquired 15,362 put options on the stock. This represents an increase of approximately 229% compared to the average daily volume of 4,673 put options.
Amgen (AMGN) opened at 159.53 on Wednesday. The company’s 50-day moving average price is $159.90 and its 200 day moving average price is $160.09. The firm has a market capitalization of $117.32 billion, a price-to-earnings ratio of 15.15 and a beta of 1.15. Amgen has a 52-week low of $133.64 and a 52-week high of $184.21.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.00 by $0.15. The firm had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.90 earnings per share. Equities analysts predict that Amgen will post $12.45 earnings per share for the current fiscal year.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.20% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Jackson Grant Investment Advisers Inc. raised its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Amgen by 0.5% in the third quarter. Parkside Financial Bank & Trust now owns 1,470 shares of the medical research company’s stock valued at $245,000 after buying an additional 7 shares in the last quarter. Altavista Wealth Management Inc. raised its position in Amgen by 0.3% in the fourth quarter. Altavista Wealth Management Inc. now owns 3,985 shares of the medical research company’s stock valued at $583,000 after buying an additional 10 shares in the last quarter. RKL Wealth Management LLC raised its position in Amgen by 0.9% in the first quarter. RKL Wealth Management LLC now owns 1,537 shares of the medical research company’s stock valued at $252,000 after buying an additional 13 shares in the last quarter. Finally, First Command Financial Services Inc. raised its position in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.
Several analysts have recently weighed in on AMGN shares. Jefferies Group LLC lowered Amgen from a “buy” rating to a “hold” rating and cut their price objective for the company from $194.00 to $180.00 in a report on Wednesday, April 5th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 price objective for the company in a report on Monday, March 27th. Credit Suisse Group AG restated a “hold” rating and issued a $178.00 price objective on shares of Amgen in a report on Tuesday, April 4th. Cowen and Company restated an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a report on Wednesday, April 19th. Finally, Mizuho set a $195.00 price objective on Amgen and gave the company a “buy” rating in a report on Thursday, March 16th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Amgen currently has a consensus rating of “Buy” and an average target price of $186.89.
ILLEGAL ACTIVITY NOTICE: This report was reported by Mideast Time and is the property of of Mideast Time. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.mideasttime.com/amgen-target-of-unusually-high-options-trading-amgn/1757891.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.